The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison
to placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Study design:
double-blind, randomized, placebo-controlled, parallel-groups, fixed-dose design, multicentre
study.